Enliven Therapeutics (NASDAQ:ELVN) Price Target Raised to $56.00 at HC Wainwright

Enliven Therapeutics (NASDAQ:ELVN) had its target price raised by HC Wainwright from $48.00 to $56.00 in a research report released on Thursday,Benzinga reports. They currently have a buy rating on the stock.

Other equities analysts have also issued reports about the company. Wall Street Zen lowered Enliven Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Mizuho lifted their price target on shares of Enliven Therapeutics from $41.00 to $45.00 and gave the stock an “outperform” rating in a research note on Wednesday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Wednesday, January 21st. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $43.40.

Enliven Therapeutics Price Performance

Shares of Enliven Therapeutics stock opened at $39.29 on Thursday. Enliven Therapeutics has a 1-year low of $13.30 and a 1-year high of $40.62. The company has a market capitalization of $2.35 billion, a PE ratio of -21.12 and a beta of 0.33. The business has a 50-day moving average of $28.32 and a 200-day moving average of $22.84.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.06). On average, equities analysts expect that Enliven Therapeutics will post -1.95 earnings per share for the current fiscal year.

Insider Transactions at Enliven Therapeutics

In other news, Director Richard A. Heyman sold 9,635 shares of Enliven Therapeutics stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $25.03, for a total value of $241,164.05. Following the completion of the transaction, the director directly owned 25,545 shares of the company’s stock, valued at approximately $639,391.35. The trade was a 27.39% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Benjamin Hohl sold 10,000 shares of the business’s stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $29.58, for a total transaction of $295,800.00. Following the sale, the chief financial officer directly owned 51,000 shares of the company’s stock, valued at approximately $1,508,580. This represents a 16.39% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 232,180 shares of company stock valued at $6,217,033. Company insiders own 25.90% of the company’s stock.

Hedge Funds Weigh In On Enliven Therapeutics

A number of large investors have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Enliven Therapeutics by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after purchasing an additional 594 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after purchasing an additional 930 shares during the last quarter. Los Angeles Capital Management LLC acquired a new position in Enliven Therapeutics during the 4th quarter valued at approximately $83,000. Quantbot Technologies LP grew its stake in Enliven Therapeutics by 47.1% during the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after buying an additional 1,434 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Enliven Therapeutics during the 4th quarter worth $95,000. Institutional investors own 95.08% of the company’s stock.

Trending Headlines about Enliven Therapeutics

Here are the key news stories impacting Enliven Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its price target to $56 and maintained a Buy rating, implying sizable upside versus recent levels — a clear catalyst for investor demand. HC Wainwright raises PT to $56 (Benzinga)
• Positive Sentiment: Mizuho boosted its target to $45 and set an Outperform rating, reinforcing the analyst upgrade momentum and providing additional institutional validation. Mizuho raises PT to $45 (Benzinga)
• Positive Sentiment: Merck’s $6.7B acquisition of Terns lifted sentiment across the oncology group and directly benefited Enliven by highlighting the value of blood-cancer programs, which helped spark a large intraday jump in ELVN shares. Merck buys Terns — ELVN share reaction (MSN)
• Positive Sentiment: Coverage notes that ELVN has hit new multi‑year and 52‑week highs as analysts turn upbeat, which can attract momentum and crossover buying from funds tracking breakouts. ELVN hits 52-week high (American Banking News)
• Neutral Sentiment: Several media outlets and aggregator posts are amplifying the price-target changes and deal-driven optimism; this increases visibility but doesn’t change fundamentals immediately. Coverage roundup (Kalkine Media)

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.